

**NATIONAL INSTITUTE FOR HEALTH AND CARE
EXCELLENCE**

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

**STA Glasdegib with chemotherapy for untreated acute
myeloid leukaemia**

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

None identified during consultation. However, people who are not eligible for intensive chemotherapy may include people who are aged 75 or older and people aged under 75 with heart, lung, liver or kidney or an elevated Eastern Cooperative Oncology Group score. The final scope includes treatment options for people who are not eligible for intensive chemotherapy.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the committee?

It is anticipated that the committee's recommendations will apply regardless of age, and dependent on the marketing authorisation wording, but the committee will consider the population during the development of the appraisal to ensure that any recommendations do not directly or indirectly discriminate on the basis of age. The final scope includes treatment options for people who are not eligible for intensive chemotherapy.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No, the population not eligible for intensive chemotherapy is already described in the background section of the scope.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No

Approved by Associate Director (name):Frances Sutcliffe

Date: 03/09/2019